: Genital infection by the obligate intracellular pathogen, Chlamydia trachomatis, is the most common bacterial sexually transmitted disease (STD) in the United States, with four million reported annual cases that cost over $2 billion. Of major pathophysiological significance is the propensity for cervical infection in women to spread into the upper genital tract, provoking serious complications such as pelvic inflammatory disease, fallopian tube scarring, ectopic pregnancy and infertility. Also, the frequently asymptomatic infections do cause severe irreversible complications to be the first evidence of an infection. There are concerns that genital chlamydial disease, like certain other STDs, such as AIDS and gonococcal disease, may pose a serious threat to human reproduction, well-being and healthcare costs. Current control and prevention strategies target frequent screening for early detection and treatment, and development of vaccines as the priority. The search for a chlamydial vaccine has led to extensive research to define the crucial immune effectors in anti-chlamydial immunity, identify antigens that elicit protective immunity, and design effective methods of vaccine delivery. Our research has been focused on identifying the relevant immune parameters in chlamydial immunity and elucidating the mechanism(s) of intraepithelial inhibition of chlamydiae. Our findings and reports by others have culminated in a new paradigm for designing vaccines against Chlamydia based on the induction of local mucosal TH1 response. The major challenge at this stage is to select an appropriate immunogen(s) and design an effective delivery system, to induce high levels of local genital mucosal Th1 response to maintain long-term immunity. Accordingly, this proposal uses immunological, genetic engineering, molecular, cellular and biochemical techniques to investigate the central hypothesis that protective anti-chlamydial immunity will be established if immunogenic chlamydial antigen(s) are effectively delivered to induce high frequency of specific Th1 cells in the genital mucosa. Specific studies planned will use genetically engineered and wild type mice to: (a) investigate the efficacy of genetically designed recombinant multi-subunit vaccines composed of mucosal bacterial ghosts co-expressing multiple membrane proteins of C. trachomatis; (b) assess the therapeutic benefits of an immunotherapeutic cellular vaccine based on IL-lO gene-suppressed dendritic cells presenting antigens for inducing high frequency of specific Th1 response, as an alternative therapeutic vaccine for C. trachomatis; (c) identify the major mucosal inductive sites, antigen-presenting cells and other accessory cells crucial for Th1 activation; and (d) define the molecular and cellular elements regulating Th1 activation, trafficking and recruitment into the genital mucosa following effective cellular and subunit vaccination against C. trachomatis. Results from these studies will likely lead to the development of a reliable vaccine regimen against Chlamydia, which should have major implications for the genital, ocular, and lung infections and their complications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
2R01AI041231-06
Application #
6331908
Study Section
Bacteriology and Mycology Subcommittee 2 (BM)
Program Officer
Quackenbush, Robert L
Project Start
1996-09-01
Project End
2006-06-30
Budget Start
2001-09-01
Budget End
2002-06-30
Support Year
6
Fiscal Year
2001
Total Cost
$328,267
Indirect Cost
Name
Morehouse School of Medicine
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
City
Atlanta
State
GA
Country
United States
Zip Code
30310
Donaldson, G P; Ladinsky, M S; Yu, K B et al. (2018) Gut microbiota utilize immunoglobulin A for mucosal colonization. Science 360:795-800
Igietseme, Joseph U; Omosun, Yusuf; Nagy, Tamas et al. (2018) Molecular Pathogenesis of Chlamydia Disease Complications: Epithelial-Mesenchymal Transition and Fibrosis. Infect Immun 86:
Pan, Qing; Zhang, Qiang; Chu, Jun et al. (2017) Chlamydia abortus Pmp18.1 Induces IL-1? Secretion by TLR4 Activation through the MyD88, NF-?B, and Caspase-1 Signaling Pathways. Front Cell Infect Microbiol 7:514
Pan, Qing; Pais, Roshan; Ohandjo, Adaugo et al. (2015) Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model. Vaccine 33:1865-72
Igietseme, Joseph U; Omosun, Yusuf; Stuchlik, Olga et al. (2015) Role of Epithelial-Mesenchyme Transition in Chlamydia Pathogenesis. PLoS One 10:e0145198
Eko, Francis O; Mania-Pramanik, Jayanti; Pais, Roshan et al. (2014) Vibrio cholerae ghosts (VCG) exert immunomodulatory effect on dendritic cells for enhanced antigen presentation and induction of protective immunity. BMC Immunol 15:584
Igietseme, Joseph U; Omosun, Yusuf; Partin, James et al. (2013) Prevention of Chlamydia-induced infertility by inhibition of local caspase activity. J Infect Dis 207:1095-104
Igietseme, Joseph U; Eko, Francis O; Black, Carolyn M (2011) Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines 10:1585-96
Eko, F O; Okenu, D N; Singh, U P et al. (2011) Evaluation of a broadly protective Chlamydia-cholera combination vaccine candidate. Vaccine 29:3802-10
Eko, F O; Ekong, E; He, Q et al. (2011) Induction of immune memory by a multisubunit chlamydial vaccine. Vaccine 29:1472-80

Showing the most recent 10 out of 41 publications